Dyadic International, Inc. (Nasdaq: DYAI) , d/b/a Dyadic Applied BioSolutions (“Dyadic” or the “Company”), a biotechnology company focused on the development and commercialization of scalable ...
Upon exercise of the option, Dyadic would receive a milestone payment in the mid-seven figures and Janssen would have the right to add additional non-exclusive targets to the collaboration. Dyadic ...
JUPITER, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology ...
JUPITER, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for ...
JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a ...
JUPITER, Fla., March 20, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a ...
JUPITER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a ...
Joseph P. Hazelton, President & COO, stated Dyadic has shifted from a platform-focused R&D company to a commercially-driven biotechnology business, emphasizing, "We are now at the commercial ...
Demonstrated substantial revenue increase for Q3 2024, driven primarily by Dapibus™ license fees and milestone payments. Received $1 million milestone payment for animal-free recombinant albumin ...
Webcast Link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=qVNgtGJ6 An archive of the webcast will be available within 24 hours after completion of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results